Cargando…

A Primary Evaluation of Potential Small‐Molecule Inhibitors of the Astacin Metalloproteinase Ovastacin, a Novel Drug Target in Female Infertility Treatment

Despite huge progress in hormonal therapy and improved in vitro fertilization methods, the success rates in infertility treatment are still limited. A recently discovered mechanism revealed the interplay between the plasma protein fetuin‐B and the cortical granule‐based proteinase ovastacin to be a...

Descripción completa

Detalles Bibliográficos
Autores principales: Körschgen, Hagen, Jäger, Christian, Tan, Kathrin, Buchholz, Mirko, Stöcker, Walter, Ramsbeck, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496240/
https://www.ncbi.nlm.nih.gov/pubmed/32946206
http://dx.doi.org/10.1002/cmdc.202000397
_version_ 1783583053624377344
author Körschgen, Hagen
Jäger, Christian
Tan, Kathrin
Buchholz, Mirko
Stöcker, Walter
Ramsbeck, Daniel
author_facet Körschgen, Hagen
Jäger, Christian
Tan, Kathrin
Buchholz, Mirko
Stöcker, Walter
Ramsbeck, Daniel
author_sort Körschgen, Hagen
collection PubMed
description Despite huge progress in hormonal therapy and improved in vitro fertilization methods, the success rates in infertility treatment are still limited. A recently discovered mechanism revealed the interplay between the plasma protein fetuin‐B and the cortical granule‐based proteinase ovastacin to be a novel key mechanism in the regulation of fertilization. Upon sperm–egg fusion, cleavage of a distinct zona pellucida component by ovastacin destroys the sperm receptor, enhances zona robustness, and eventually provides a definitive block against polyspermy. An untimely onset of this zona hardening prior to fertilization would consequently result in infertility. Physiologically, this process is controlled by fetuin‐B, an endogenous ovastacin inhibitor. Here we aimed to discover small‐molecule inhibitors of ovastacin that could mimic the effect of fetuin‐B. These compounds could be useful lead structures for the development of specific ovastacin inhibitors that can be used in infertility treatment or in vitro fertilization
format Online
Article
Text
id pubmed-7496240
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74962402020-09-25 A Primary Evaluation of Potential Small‐Molecule Inhibitors of the Astacin Metalloproteinase Ovastacin, a Novel Drug Target in Female Infertility Treatment Körschgen, Hagen Jäger, Christian Tan, Kathrin Buchholz, Mirko Stöcker, Walter Ramsbeck, Daniel ChemMedChem Communications Despite huge progress in hormonal therapy and improved in vitro fertilization methods, the success rates in infertility treatment are still limited. A recently discovered mechanism revealed the interplay between the plasma protein fetuin‐B and the cortical granule‐based proteinase ovastacin to be a novel key mechanism in the regulation of fertilization. Upon sperm–egg fusion, cleavage of a distinct zona pellucida component by ovastacin destroys the sperm receptor, enhances zona robustness, and eventually provides a definitive block against polyspermy. An untimely onset of this zona hardening prior to fertilization would consequently result in infertility. Physiologically, this process is controlled by fetuin‐B, an endogenous ovastacin inhibitor. Here we aimed to discover small‐molecule inhibitors of ovastacin that could mimic the effect of fetuin‐B. These compounds could be useful lead structures for the development of specific ovastacin inhibitors that can be used in infertility treatment or in vitro fertilization John Wiley and Sons Inc. 2020-07-02 2020-08-19 /pmc/articles/PMC7496240/ /pubmed/32946206 http://dx.doi.org/10.1002/cmdc.202000397 Text en © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Communications
Körschgen, Hagen
Jäger, Christian
Tan, Kathrin
Buchholz, Mirko
Stöcker, Walter
Ramsbeck, Daniel
A Primary Evaluation of Potential Small‐Molecule Inhibitors of the Astacin Metalloproteinase Ovastacin, a Novel Drug Target in Female Infertility Treatment
title A Primary Evaluation of Potential Small‐Molecule Inhibitors of the Astacin Metalloproteinase Ovastacin, a Novel Drug Target in Female Infertility Treatment
title_full A Primary Evaluation of Potential Small‐Molecule Inhibitors of the Astacin Metalloproteinase Ovastacin, a Novel Drug Target in Female Infertility Treatment
title_fullStr A Primary Evaluation of Potential Small‐Molecule Inhibitors of the Astacin Metalloproteinase Ovastacin, a Novel Drug Target in Female Infertility Treatment
title_full_unstemmed A Primary Evaluation of Potential Small‐Molecule Inhibitors of the Astacin Metalloproteinase Ovastacin, a Novel Drug Target in Female Infertility Treatment
title_short A Primary Evaluation of Potential Small‐Molecule Inhibitors of the Astacin Metalloproteinase Ovastacin, a Novel Drug Target in Female Infertility Treatment
title_sort primary evaluation of potential small‐molecule inhibitors of the astacin metalloproteinase ovastacin, a novel drug target in female infertility treatment
topic Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496240/
https://www.ncbi.nlm.nih.gov/pubmed/32946206
http://dx.doi.org/10.1002/cmdc.202000397
work_keys_str_mv AT korschgenhagen aprimaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT jagerchristian aprimaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT tankathrin aprimaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT buchholzmirko aprimaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT stockerwalter aprimaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT ramsbeckdaniel aprimaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT korschgenhagen primaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT jagerchristian primaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT tankathrin primaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT buchholzmirko primaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT stockerwalter primaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment
AT ramsbeckdaniel primaryevaluationofpotentialsmallmoleculeinhibitorsoftheastacinmetalloproteinaseovastacinanoveldrugtargetinfemaleinfertilitytreatment